Nebivolol: The Cardioselective Beta Blocker That Releases Nitric Oxide
Last updated: March 2026
Nebivolol combines the highest β1-selectivity of any beta blocker (293-fold over β2) with a unique nitric oxide-releasing vasodilatory mechanism. Unlike older beta blockers, it reduces blood pressure without the metabolic penalties — making it the preferred choice for on-cycle cardiovascular protection.
Highest of Any Beta Blocker
Once-Daily Oral
SENIORS HF Trial
📋 On this page
How Nebivolol Works
Nebivolol is a third-generation beta-blocker with a dual mechanism that distinguishes it from all older agents. Its extraordinary β1 selectivity confines cardiac effects to the heart, while its unique ability to stimulate endothelial nitric oxide synthase (eNOS) causes arterial vasodilation — a property no other beta blocker possesses to this degree.
Nebivolol selectively blocks cardiac β1 adrenergic receptors with 293-fold selectivity over β2 receptors. This slows heart rate (negative chronotropy) and reduces force of contraction (negative inotropy), lowering cardiac output and blood pressure. The extreme selectivity spares bronchial and peripheral β2 receptors, minimizing bronchoconstriction and metabolic disruption.
Uniquely among beta blockers, nebivolol stimulates endothelial nitric oxide synthase (eNOS) via a β3 receptor-mediated pathway. This increases vascular NO production, causing arterial vasodilation and reducing peripheral vascular resistance. This NO-mediated mechanism is why nebivolol lowers BP without the peripheral vasoconstriction seen with older beta blockers.
Chronic nebivolol use improves endothelial function beyond blood pressure reduction. Increased NO bioavailability reduces oxidative stress, decreases vascular inflammation, and improves flow-mediated dilation (FMD). This is particularly relevant during anabolic steroid use, which is known to impair endothelial function and NO bioavailability over time.
Unlike non-selective beta blockers (propranolol) or even moderately selective agents (metoprolol), nebivolol does not significantly impair insulin sensitivity, raise triglycerides, or reduce HDL cholesterol. Its vasodilatory mechanism prevents the insulin resistance and dyslipidemia associated with older beta blockers — critical for athletes and those already managing lipid profiles.
What the Clinical Trials Show
Data from SENIORS, ENECA, NEBIS, and comparative trials vs. other beta blockers.
Side Effects & Risks
Key Takeaways
- Most β1-selective beta blocker available — 293-fold selectivity over β2
- Unique eNOS-mediated NO release causes vasodilation — unlike all other BBs
- Reduces BP ~7.3 mmHg systolic and HR ~12 bpm at therapeutic dose
- Significantly less erectile dysfunction than atenolol/metoprolol
- Metabolically neutral — does not impair insulin sensitivity or raise TGs
- Reduces CV death/hospitalization 14% in elderly HF patients (SENIORS)
- Outcome data specifically in AAS/TRT users is lacking
- Optimal cycling protocol (whether to continue off-cycle)
- Exercise performance impact at higher doses in athletes
- Long-term NO-upregulation effects in healthy, non-HF individuals
🛒 Recommended Products
Monitoring supplies for nebivolol therapy and blood pressure tracking.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational purposes only. It is not medical advice. Nebivolol is a prescription medication. Never stop a beta blocker abruptly — abrupt discontinuation can cause rebound hypertension, tachycardia, and angina. Always taper under physician supervision. Do not use in severe bradycardia, heart block, or severe asthma without medical clearance.